EPI-7386 inhibits cell proliferation across a panel of prostate cancer cell lines, including those driven by the AR variant AR-V7, can control tumor growth and induce tumor regression in several CRPC xenograft models, and is well tolerated in animal models [50, 51]. Here, AR is linked to neoplasm.